Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

XPhyto: Is Mescaline the Next Big Mood-Modifying Medicine?

It has the potential to be the next frontier in the psychedelics renaissance, and it represents an unprecedented opportunity to innovate a notable advancement in mental health therapy. In anecdotal studies, mescaline has shown promise in treating depression, anxiety, PTSD,...
Marc Davis | April 6, 2021 |

Financial Antivirus Stimulus Packages and Gold

The new coronavirus is unfortunately deadly not only for humans but also for global economy. The central banks have shot their bazookas, but the monetary policy is helpless during pandemics . So it didn’t take long to persuade governments to intervene and in...
Arkadiusz Sieron | April 27, 2020 |

ExoTherapy offers hope for treating acute spinal cord injuries

Suffering from traumatic injuries can leave a person with long-term damages and/or side effects that are hard to navigate long after the initial incident has passed. Our next company is a publicly traded bio-pharmaceutical company, working on the development of its ...
Brieanna McCutcheon | September 19, 2023 |

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure ...
Streetwise Reports | November 15, 2019 |

Flying Under the Radar with a Possible COVID-19 Treatment

Investors would think a pharmaceutical company heading into Phase 2b/3 human trials for treating the third most malignant disease after lung cancer and pancreatic cancer would draw eyes from major players. If that same company announced it was embarking on Phase2b/3 human tri...
Stockhouse Editorial | September 8, 2020 |

'Undervalued' Biopharma Features Robust Pipeline, Future Upside

The case for investing in this company was made in an H.C. Wainwright & Co. report. In an April 22, 2019 research note, analyst Ram Selvaraju reported that H.C. Wainwright & Co. initiated coverage on Aquestive Therapeutics Inc. (AQST:NASDAQ) , "an undervalued spec...
Streetwise Reports | April 29, 2019 |

PODCAST: A CBD-focused First-to-Market Franchise Model

This podcast is part of our Cannabis Sector CEO interview series. The focus of our new StockTalk Podcasts is to help listeners and investors learn about, understand, and discover investment opportunities in the public marketplace.   Stockhouse Media's Dave Jackson was r...
Dave Jackson | September 19, 2019 |

Forging a New Path into the Medical Cannabis Space

Although 2019 was in many ways ‘The Year that the Cannabis Sector Would Like to Forget’, there are many pioneering ways that a company can take to generate revenue in the still-emerging medical cannabis and CBD markets. One such company has been advancing st...
Dave Jackson | February 13, 2020 |

The Company That’s Delivering Safe, Evidence-Based Psychedelic-Assisted Psychotherapies

(Click image to play podcast) Stockhouse investors who are dialed into the not-only nascent but now, pardon the pun, mushrooming psychedelics sector are likely familiar with a mental health and wellness company “centred on developing and supporting the safe, ev...
Dave Jackson | October 8, 2020 |

A New Frontier in Psychedelic Therapeutics

Cybin X Kernel "A New Frontier in Psychedelic Therapeutics" About the partnership: Cybin Corporation ( N.CYBN , Forum ) will leverage Kernel’s Flow to quantify brain activity during psychedelic experiences in re...
Featured Submission | January 11, 2021 |
1 2 3 4 5 6 7 8 9 10